History of Wilson's disease: 1912 to 2000

Movement Disorders

Volumn 21, Issue 2, 2006, Pages 142-147

  Walshe, John M ^a,b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER; COPPER EXPORTING ADENOSINE TRIPHOSPHATASE; COPPER PROTEIN; DIMERCAPROL; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; WILSON DISEASE PROTEIN; ZINC DERIVATIVE; ZINC SULFATE;

AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOME 13Q; CLINICAL FEATURE; COPPER METABOLISM; DISEASE ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HEMOLYSIS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; LONG TERM CARE; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE LEVEL; UNSPECIFIED SIDE EFFECT; WILSON DISEASE;

ENGLAND; HEPATOLENTICULAR DEGENERATION; HISTORY, 20TH CENTURY; HUMANS;

EID: 33644959308     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20694     Document Type: Review

References (62)

1. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912;34: 295-507.
2. Frerichs FT. A clinical treatise on diseases of the liver. Vol. 1. London: Trans Murchison C New Sydenham Soc; 1860.
3. Morgagni GB. De sedibus et causis morborum. London: Trans B Alexander; 1761.
4. Kayser B. Ueber einen fall von angeborener grunlicher verfarbung der cornea. Klin Mbl Augenheilk 1902;40:22-25.
5. Wilson SAK. La maladie de Wilson. In: Marie P, editor. Questions Neurologiques d'Actualite. Paris: Mason; 1922.
6. Scheinberg IH, Sternlieb I. Wilson's disease. Philadelphia: WB Saunders; 1984.
7. Critchley M, Remembering Kinnear Wilson. Mov Disord 1988;3: 2-6.
8. Cumings JN. The copper and iron content of brain and liver in the normal and in hepatolenticular degeneration. Brain 1948;71:410-415.
9. Rumpel A. Uber das Wesen und die Bedeutung der Leberveranderungen und der pigmentierunen bie den damit verbunden Fallen von Pseudosclerose, zugleich ein Beitrag zur Lehre von der Pseudosclerose (Westphal-Strumpell). Dtsch Z Nervenheilk 1913; 49:54-73.
10. Bramwell B. Familial cirrhosis of the liver: four cases of acute fatal cirrhosis in the same family, the patients being respectively nine, ten, fourteen and fourteen years of age: suggested relationship to Wilson's progressive degeneration of the lenticular nucleus. Edin Med J 1916;17:90-99.
11. Hall HC. La degenerescence Hepatolenticulare. Maladie de Wilson-pseudosclerose. Paris: Mason; 1921.
12. Bearn AG. A genetical analysis of 30 families with Wilson's disease (hepatolenticular degeneration). Ann Hum Genet 1960;24: 33-43.
13. Siemerling E, Oloff H. Pseudosclerose (Westphal-Strumpell) mit cornealring (Kayser-Fleischer) und doppelseitger scheinkatarakt, die nur bei seitlicherbeleuchtung sichtbar ist und die, der nach verletzung durch kupfersplitterentstehenden katarakt ahnlich ist. Klin Wschr 1922;1:1087-1089.
14. Vogt A. Kupfer und silber aufgespeichert in auge, leber, milz und nieren als symptom der pseudosklerose. Klin Mbl Augenheilk 1929;83:417-419.
15. Haurowitz F. Ubereine anamoliedes kupferstoffwechsels. Hoppe-Seyl Z 1930;190:72-74.
16. Glazebrook AJ. Wilson's disease. Edin Med J 1945;52:83-87.
17. Peters RA, Stocken LA, Thompson RHS. Britishantilewisite (BAL). Nature (Lond) 1945;15:656.
18. Mandlebrote BM, Stanier MW, Thompson RHS, Thurston MN. Studies on copper metabolism in demyelinating diseases of the central nervous system. Brain 1948;71:212-228.
19. Cumings JN. The effects of BAL in hepatolenticular degeneration. Brain 1951;74:10-22.
20. Denny Brown D, Porter H. The effects of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N Engl J Med 1951;245:917-925.
21. Vilensky JY, Robertson WA, Gilman S. Denny-Brown Wilson's disease and BAL (British antilewisite, 2,3-dimercaptopropanol). Neurology 2002;59:914-916.
22. Scheinberg IH, Gitlin D. Deficiency of caeruloplasmin in patients with hepato-lenticular degeneration (Wilson's disease). Science 1952;116:484-485.
23. Bearn AG, Kunkel HG. Biochemical abnormalities in Wilson's disease. J Clin Invest 1952;31:616.
24. Holmberg CG, Laurell C-B. Investigations in serum copper. II. Isolation of the copper containing protein, and a description of its properties. Acta Chem Scand 1948;2:550-556.
25. Cartwright GE, Hodges RE, Gubler CJ, et al. Studies on copper metabolism. XII. Hepatolenticular degeneration. J Clin Invest 1954;33:1487-1501.
26. Bearn HG, Kunkel HG. Localisation of Cu64 in serum fractions following oral administration: an alteration in Wilson's disease. Proc Soc exp Biol 1954;85:44-48.
27. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956;21:487-495.
28. Walshe JM. The story of penicillamine: a difficult birth. Mov Disord 2003;18:853-859.
29. Walshe JM. The treatment of Wilson's disease with penicillamine. Lancet 1960;1:188-192.
30. Scheinberg IH, Sternlieb I. Long-term management of hepatolenticular degeneration (Wilson's disease). Am J Med 1960;29:316-333.
31. Uzman LL, Iber FL, Chalmers TC, Knowlton M. The mechanism of copper deposition in the liver in hepatolenticular degeneration (Wilson's disease). Am J Med Sci 1956;231:511-518.
32. Walshe JM. Wilson's disease. The presenting symptoms. Arch Dis Child 1962;37:253-256.
33. Bearn AG. Wilson's disease. An inborn error of metabolism with multiple manifestations. Am J Med 1957;22:747-757.
34. Walshe JM. Copper: its role in the pathogenesis of liver disease. Semin liver Dis 1984;4:252-263.
35. Uzman LL, Hood B. The familial nature of the amino-aciduria of Wilson's disease. Am J Med Sci 1952;223:392-400.
36. Asatoor AM, Milne MD, Walshe JM. The urinary excretion of peptides and hydroxyproline in Wilson's disease. Clin Sci Mol Med 1976;51:369-378.
37. Asatoor AM, Milne MD, Walshe JM. The effect of chelation therapy on the amino aciduria and peptiduria of Wilson's disease. J R Coll Phys Lond1983;17:122-125.
38. Cumings JN. Heavy metals and the brain. Oxford: Blackwell Scientific Publications; 1959.
39. Osborn SB, Roberts CN, Walshe JM. Uptake of radiocopper by the liver. A study of patients with Wilson's disease and various control groups. Clin Sci 1963;24:14-22.
40. Osborn SB, Walshe JM. Studies with radiocopper (64Cu) in Wilson's disease: the liver/thigh ratio. Clin Sci 1964;27:319-328.
41. Osborn SB, Walshe JM. Studies with radiocopper (64Cu) in Wilson's disease: the dynamics of copper transport. Clin Sci 1965;29: 575-581.
42. Osborn SB, Walshe JM. Studies with radioactive copper (64Cu, 67Cu) in relation to the natural history of Wilson's disease. Lancet 1967;1:346-350.
43. Gibbs K, Walshe JM. Studies with radioactive copper (64Cu, 67Cu); the incorporation of radioactive copper into caeruloplasmin in Wilson's disease and in primary biliary cirrhosis. Clin Sci 1971;41:189-202.
44. Walshe JM, Potter G. The pattern of whole body distribution of radioactive copper (67Cu, 64Cu) in Wilson's disease and various control groups. Q J Med 1977;46:445-462.
45. Gibbs K, Walshe JM. Biliary excretion of copper in Wilson's disease. Lancet 1980;2:538-539.
46. Walshe JM. Hudson Memorial Lecture. Wilson's disease: genetics and biochemistry - their relevance to therapy. J Inherit Metab Dis 1983;6(Suppl. 1):51-58.
47. Sherlock S, McIntyre N, Clink HM, Levi AJ, Cumings JN. Haemolytic anaemia in Wilson's disease. In: Bergsma S, Scheinberg IH, Sternlieb I, editors. Wilson's disease. Birth defects, original article series. Vol. IV. New York: The National Foundation-March of Dimes; 1968. p 99-102.
48. Roche-Sicot J, Benhamou JN, Acute intravascular haemolysis and acute liver failure associated as a first manifestation of Wilson's disease. Ann Intern Med 1977;86:301-303.
49. Schouwink G. De Hepato-cerebraledegeneratie (met een onderzoek van de Zinkstofwisseling). Durk: GW van der Wiel & Co Arnhem; 1961.
50. Hoogenraad TU, Koevoet R, de Ruyter Korvet EG. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol 1979;18:205-211.
51. Brewer CJ, Prasad AS, Cossack ZT, Rabbani PI. Treatment of Wilson's disease with oral zinc. Clin Res 1981;29:758.
52. Walshe JM. Toxic reactions to penicillamine in patients with Wilson's disease. Post Grad Med J 1968;(Suppl.):6-8.
53. Walshe JM. Triethylene tetramine dihydrochloride; a new chelating agent for copper. In: Karch FE, editor. Orphan drugs. New York: Marcel Dekker Inc; 1982.
54. Starzl TE, Iwatuski S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology 1982;2:614-636.
55. Sutcliffe RP, Maguire DD, Muiesan P, et al. Liver transplantation for Wilson's disease: long term results and quality of life assessment. Transplantation 2003;15:1003-1006.
56. Walshe JM. Copper: its role in the pathogenesis of liver disease. Semin Liver Dis 1984;4:252-263.
57. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, et al. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991;48:42-47.
58. Bickel H, Neale FC, Hall G. A clinical and biochemical study of hepatolenticular degeneration (Wilson's disease). Q J Med 1957,26:527-558.
59. Bull PC, Thomas GR, Rommens JN, Fox JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;54:327-337.
60. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes gene. Nat Genet 1993;5:44-50.
61. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993;197:271-277.
62. Cox DW, Kenney S. Wilson disease database. Available online at http://www